214 related articles for article (PubMed ID: 30952723)
1. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
Mego M; Karaba M; Minarik G; Benca J; Silvia J; Sedlackova T; Manasova D; Kalavska K; Pindak D; Cristofanilli M; Reuben JM; Mardiak J
Anticancer Res; 2019 Apr; 39(4):1829-1837. PubMed ID: 30952723
[TBL] [Abstract][Full Text] [Related]
2. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
[TBL] [Abstract][Full Text] [Related]
3. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.
Mego M; Mani SA; Lee BN; Li C; Evans KW; Cohen EN; Gao H; Jackson SA; Giordano A; Hortobagyi GN; Cristofanilli M; Lucci A; Reuben JM
Int J Cancer; 2012 Feb; 130(4):808-16. PubMed ID: 21387303
[TBL] [Abstract][Full Text] [Related]
4. Epithelial‑mesenchymal transition was identified as a potential marker for breast cancer aggressiveness using reverse transcription‑quantitative polymerase chain reaction.
Andergassen U; Schlenk K; Jeschke U; Sommer H; Kölbl A
Mol Med Rep; 2018 Aug; 18(2):1733-1739. PubMed ID: 29845200
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
[TBL] [Abstract][Full Text] [Related]
6. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer.
Mego M; Cholujova D; Minarik G; Sedlackova T; Gronesova P; Karaba M; Benca J; Cingelova S; Cierna Z; Manasova D; Pindak D; Sufliarsky J; Cristofanilli M; Reuben JM; Mardiak J
BMC Cancer; 2016 Feb; 16():127. PubMed ID: 26896000
[TBL] [Abstract][Full Text] [Related]
7. Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients.
Bystricky B; Cierna Z; Sieberova G; Janega P; Karaba M; Minarik G; Benca J; Sedlackova T; Jurisova S; Gronesova P; Pindak D; Macuch J; Mardiak J; Mego M
Anticancer Res; 2017 May; 37(5):2727-2734. PubMed ID: 28476852
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
[TBL] [Abstract][Full Text] [Related]
9. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
[TBL] [Abstract][Full Text] [Related]
10. Expression of EMT Markers SLUG and TWIST in Breast Cancer.
Grzegrzolka J; Biala M; Wojtyra P; Kobierzycki C; Olbromski M; Gomulkiewicz A; Piotrowska A; Rys J; Podhorska-Okolow M; Dziegiel P
Anticancer Res; 2015 Jul; 35(7):3961-8. PubMed ID: 26124343
[TBL] [Abstract][Full Text] [Related]
11. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
13. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
Kasimir-Bauer S; Hoffmann O; Wallwiener D; Kimmig R; Fehm T
Breast Cancer Res; 2012 Jan; 14(1):R15. PubMed ID: 22264265
[TBL] [Abstract][Full Text] [Related]
14. Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.
Bystricky B; Jurisova S; Karaba M; Minarik G; Benca J; Sedlácková T; Tothova L; Vlkova B; Cierna Z; Janega P; Manasova D; Gronesova P; Pindak D; Mardiak J; Celec P; Mego M
Anticancer Res; 2017 Apr; 37(4):1787-1791. PubMed ID: 28373442
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
[TBL] [Abstract][Full Text] [Related]
17. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion.
Imani S; Wei C; Cheng J; Khan MA; Fu S; Yang L; Tania M; Zhang X; Xiao X; Zhang X; Fu J
Oncotarget; 2017 Mar; 8(13):21362-21379. PubMed ID: 28423483
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous Manifestations of Epithelial-Mesenchymal Plasticity of Circulating Tumor Cells in Breast Cancer Patients.
Tashireva LA; Savelieva OE; Grigoryeva ES; Nikitin YV; Denisov EV; Vtorushin SV; Zavyalova MV; Cherdyntseva NV; Perelmuter VM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801519
[TBL] [Abstract][Full Text] [Related]
20. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
